SESN Sesen Bio Inc.

0.89
-0.04  -4%
Previous Close 0.93
Open 0.94
Price To Book 44.52
Market Cap 93,206,530
Shares 104,679,391
Volume 1,187,194
Short Ratio
Av. Daily Volume 1,558,336
Stock charts supplied by TradingView

NewsSee all news

  1. Sesen Bio Initiates Rolling Submission of BLA for Vicinium to FDA

    Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that on December 6, 2019, the Company initiated the

  2. Sesen Bio Completes Successful CMC Type B pre-BLA Meeting with FDA

    Company gained FDA alignment on the final content of the BLA Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today

  3. Sesen Bio Reports Third Quarter 2019 Financial Results and Update on Regulatory Activities Related to Vicinium

    On Track for Anticipated Initiation of BLA Submission in December, 2019 Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer,

  4. Sesen Bio Announces Successful Type C Meeting with FDA for Vicinium

    Alignment reached with FDA on post-marketing confirmatory trial design Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer,

  5. Sesen Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the H.C.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Rolling BLA filing commenced December 6, 2019.
Vicinium
Non-muscle invasive bladder cancer (NMIBC)

Latest News

  1. Sesen Bio Initiates Rolling Submission of BLA for Vicinium to FDA

    Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that on December 6, 2019, the Company initiated the

  2. Sesen Bio Completes Successful CMC Type B pre-BLA Meeting with FDA

    Company gained FDA alignment on the final content of the BLA Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today

  3. Sesen Bio Reports Third Quarter 2019 Financial Results and Update on Regulatory Activities Related to Vicinium

    On Track for Anticipated Initiation of BLA Submission in December, 2019 Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer,

  4. Sesen Bio Announces Successful Type C Meeting with FDA for Vicinium

    Alignment reached with FDA on post-marketing confirmatory trial design Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer,

  5. Sesen Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the H.C.

  6. Sesen Bio Announces CFO Transition as Company Drives Towards Anticipated Initiation of BLA Submission in 4Q 2019

    Company Appoints Monica Forbes as Chief Financial Officer and Kirstin Anderson as Principal Accounting Officer